COMMUNIQUÉS West-GlobeNewswire

Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy
10/02/2025
BRIDGEWATER, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.-based medical device company focused on developing technologically [...]
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
10/02/2025
BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of the Company’s [...]
Saudi Arabia’s KFSHRC Continues to Rise as a Globally Renowned Medical Centre
09/02/2025
RIYADH, Saudi Arabia, Feb. 09, 2025 (GLOBE NEWSWIRE) -- Saudi Arabia’s King Faisal Specialist Hospital & Research Centre (KFSHRC) – the region’s top-ranked hospital – has secured 15th place in 2025 among the world’s [...]
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
08/02/2025
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks TARRYTOWN, N.Y [...]
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
08/02/2025
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year : 77%, 58%, 40% and 24% [...]
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
08/02/2025
3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks In the recently diagnosed [...]
REPEAT - MEDIA ADVISORY: Public healthcare advocates to protest at Minister of Health Sylvia Jones’ office
08/02/2025
SITUATION CRITICAL TORONTO, Feb. 08, 2025 (GLOBE NEWSWIRE) -- On Saturday February 8 th at 12 noon, the Grey Bruce, Brampton Caledon and Greater Toronto health coalitions, local chapters of the Ontario Health Coalition [...]
MEDIA ADVISORY: Public healthcare advocates to protest at Minister of Health Sylvia Jones’ office
08/02/2025
SITUATION CRITICAL TORONTO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- On Saturday February 8 th at 12 noon, the Grey Bruce, Brampton Caledon and Greater Toronto health coalitions, local chapters of the Ontario Health Coalition [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
08/02/2025
ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares. Attachments Notification of [...]
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
07/02/2025
Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, Calif., Feb. 07, [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07/02/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated therapeutics to fight cancer [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs [...]
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
07/02/2025
IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar [...]
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025
WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/02/2025
NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
07/02/2025
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and [...]

Pages